Blonanserin differs from currently used serotonin 5-HT2A/dopamine-D2 receptor antagonists for the reason that it displays higher affinity for dopamine-D2/3 receptors than for serotonin 5-HT2A receptors. not really by 7-OH-DPAT. The ameliorating impact was also antagonized by “type”:”entrez-protein”,”attrs”:”text message”:”SCH23390″,”term_id”:”1052733334″,”term_text message”:”SCH23390″SCH23390 (a dopamine-D1 receptor antagonist) and H-89 (a proteins kinase A (PKA) inhibitor). Blonanserin considerably remediated the… Continue reading Blonanserin differs from currently used serotonin 5-HT2A/dopamine-D2 receptor antagonists for the